ProShares Ultra NASDAQ Biotechnology
27 hedge funds and large institutions have $36.3M invested in ProShares Ultra NASDAQ Biotechnology in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 5 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
4% less funds holding
Funds holding: 28 → 27 (-1)
7% less capital invested
Capital invested by funds: $39.2M → $36.3M (-$2.92M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
63% less call options, than puts
Call options by funds: $14.2M | Put options by funds: $38.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$1.83M |
| 2 |
OPPM
Opus Point Partners Management
New York
|
+$1.55M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.36M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$751K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$562K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$5.23M |
| 2 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
-$4.32M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.36M |
| 4 |
Morgan Stanley
New York
|
-$979K |
| 5 |
SG Americas Securities
New York
|
-$650K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WA
26
Waverly Advisors
Birmingham,
Alabama
| $5K | – | – | – |
|
|
27
SG Americas Securities
New York
| – | -$650K | -8,200 | Closed |
|
28
HighTower Advisors
Chicago,
Illinois
| – | -$484K | -6,108 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$294K | -3,716 | Closed |
|
|
PFG
30
Piershale Financial Group
Barrington,
Illinois
| – | -$2K | -28 | Closed |
|
|
TCM
31
Tradewinds Capital Management
Bellingham,
Washington
| – | -$2K | -20 | Closed |
|
BIB Hedge Fund Activity: Q2 2015 in Review
27 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2015, worth a combined $36.3M — down 7.5% from $39.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BIB and 4 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 7 added.
The largest buyer was Creative Planning, adding an estimated $1.83M. The largest seller was Jane Street, cutting an estimated $5.23M.
- 27 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2015, down from 28 in Q1 2015.
- Funds reported $36.3M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2015, down 7.5% quarter-over-quarter.
- 4 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2015 and 5 closed out, a net change of -1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2015 was Creative Planning, an estimated $1.83M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2015 was Jane Street, an estimated $5.23M sold.
Based on aggregated 13F filings for Q2 2015.